Danske Bank A S Raises Stock Position in Eli Lilly and Company $LLY

Key Points

• Danske Bank A/S increased its Eli Lilly stake by 4.8% to 703,564 shares (adding 32,500 shares), making LLY its 10th-largest holding and about 1.8% of Danske’s portfolio; the position equals roughly 0.07% of Eli Lilly and is valued at about $756.1 million per the latest 13F.
• Eli Lilly reported a blowout quarter—EPS $8.55 vs. $6.97 estimate and revenue $19.8B (+55.5% YoY) vs. $17.82B estimate—and raised FY2026 EPS guidance to $35.50–$37.00, spurring analyst price-target increases and a consensus "Moderate Buy" (average target ~$1,217.59).

Danske Bank A S boosted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 4.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 703,564 shares of the company's stock after purchasing an additional 32,500 shares during the period. Eli Lilly and Company comprises approximately 1.8% of Danske Bank A S's investment portfolio, making the stock its 10th biggest position. Danske Bank A S owned approximately 0.07% of Eli Lilly and Company worth $756,106,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Maryland Capital Advisors Inc. acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $25,000. Miller Global Investments LLC acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $33,000. Dorato Capital Management acquired a new stake in Eli Lilly and Company in the fourth quarter valued at $36,000. Vermillion & White Wealth Management Group LLC increased its holdings in Eli Lilly and Company by 84.2% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company's stock valued at $27,000 after purchasing an additional 16 shares during the period. Finally, 10Elms LLP increased its holdings in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after purchasing an additional 10 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $967.49 on Tuesday. The firm's 50-day moving average price is $947.05 and its 200-day moving average price is $987.36. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The firm has a market capitalization of $914.11 billion, a P/E ratio of 34.37, a P/E/G ratio of 1.13 and a beta of 0.48. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. During the same quarter in the prior year, the business earned $3.34 earnings per share. The business's quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 33.79 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, May 15th. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. Eli Lilly and Company's dividend payout ratio is currently 24.58%.

Analyst Ratings Changes

A number of research firms recently weighed in on LLY. TD Cowen increased their price objective on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a "buy" rating in a report on Thursday, January 29th. Scotiabank restated an "outperform" rating and issued a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. UBS Group reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Eli Lilly and Company in a research report on Friday, March 27th. Finally, CICC Research upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a "neutral" rating in a research report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $1,217.59.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 outperformance and raised guidance — Lilly reported a blowout quarter (revenue +55% YoY, EPS well ahead of estimates) and lifted full‑year guidance, supporting the bull case for continued GLP‑1 growth. LLY Q1 Deep Dive
• Positive Sentiment: Mounjaro dominance — Reports highlight Lilly capturing roughly 60% of the GLP‑1 market and Mounjaro revenue surging, reinforcing market share and pricing power in obesity/diabetes treatments. Eli Lilly Captures 60% of the GLP‑1 Market
• Positive Sentiment: Wall Street backing — Multiple firms boosted targets and ratings (Barclays to $1,400; Wolfe reaffirmed outperform with $1,325 target; Cantor Fitzgerald and others raised views), which can sustain buying pressure. Barclays Adjusts Eli Lilly Price Target
• Positive Sentiment: Shareholder returns — Board declared a $1.73 quarterly dividend, adding incremental income support for investors. Lilly Declares Second‑Quarter 2026 Dividend
• Neutral Sentiment: Valuation/conviction pieces — Several outlets argue the pullback has made LLY's valuation more attractive (Fool, 24/7 Wall St.), offering differing price targets and buy arguments for long‑term investors. Is Eli Lilly Stock Heading for $1,000?
• Positive Sentiment: High‑profile endorsements — Media/hosts (including Jim Cramer) have publicly praised Lilly’s weight‑loss franchise and Foundayo, which can attract retail/institutional interest. Eli Lilly’s Weight Loss Pill is Better Than Novo’s, Says Jim Cramer
• Negative Sentiment: Foundayo safety signal — FDA records of liver‑failure cases tied to Foundayo prompted a near‑term selloff and caution from some investors; analysts largely view the reports as isolated but the item increases regulatory & PR risk. FDA Reports Liver Failure in Patient Taking Lilly's Foundayo

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.